Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

China

- PMLiVE

US turns spotlight on GSK bribery allegations

Department of Justice to investigate whether pharma giant contravened foreign corruption act

- PMLiVE

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

China flag thumb

GSK blamed for employee bribes in China

Xinhua news agency claims company was complicit in the payment of kickbacks to doctors

Novartis building

Novartis wins childhood arthritis indication for Ilaris in EU

EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

- PMLiVE

ReNeuron wins orphan status for stem cell therapy

ReN003 is being assessed as a treatment for rare eye disorder retinitis pigmentosa

- PMLiVE

Chiesi acquires Zymenex and mulls new rare disease unit

Deal adds late-stage orphan drug to Italian pharma company's pipeline

Shire extends rare genetic disease alliance

Agrees option with Santaris to nominate additional discovery targets

Eli Lilly HQ

Lilly is latest drugmaker drawn into China crisis

Local media reports link the pharma company to doctor bribery

China flag thumb

UK-US risk investigator team arrested in China

Corporate investigators with possible links to GSK detained

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

Novartis building

Novartis drawn into Chinese corruption probe

Former sales rep files bribery complaint about Sandostatin LAR prescribing practices

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links